Samejima Yumiko, Iuchi Atsuhiko, Kanai Tomohiro, Noda Yoshimi, Nasu Shingo, Tanaka Ayako, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Harada Hiroshi, Ezumi Akira, Ueda Kayo, Kawahara Kunimitsu, Hirashima Tomonori
Department of Thoracic Oncology, Osaka Habikino Medical Center, Japan.
Department of Cardiovascular Medicine, Osaka Habikino Medical Center, Japan.
Intern Med. 2020 Aug 15;59(16):2003-2008. doi: 10.2169/internalmedicine.4550-20. Epub 2020 May 23.
Cardiac side effects associated with immune checkpoint inhibitors (ICIs) are an uncommon but serious complication with a relatively high mortality. We experienced a case of cardiomyopathy induced by nivolumab. Echocardiography showed diffuse hypo-kinesis of the left ventricular cardiac wall and a significant decrease in the ejection fraction, like dilated cardiomyopathy. The myocardial biopsy showed non-inflammatory change; cardiac function gradually improved after treatment of acute heart failure without a corticosteroid. Although non-inflammatory left ventricular dysfunction induced by ICIs is rare, it is a reported cardiovascular toxicity. Physicians should consider this complication when treating patients with ICIs for malignant diseases.
与免疫检查点抑制剂(ICI)相关的心脏副作用是一种罕见但严重的并发症,死亡率相对较高。我们遇到了一例由纳武单抗引起的心肌病病例。超声心动图显示左心室心肌壁弥漫性运动减弱,射血分数显著降低,类似扩张型心肌病。心肌活检显示无炎症改变;在未使用皮质类固醇治疗急性心力衰竭后,心脏功能逐渐改善。尽管ICI引起的非炎性左心室功能障碍很少见,但它是一种已报道的心血管毒性。医生在治疗患有恶性疾病的ICI患者时应考虑到这种并发症。